Melanoma patients in a phase I clinic: molecular aberrations, targeted therapy and outcomes
Published 2013 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Melanoma patients in a phase I clinic: molecular aberrations, targeted therapy and outcomes
Authors
Keywords
-
Journal
ANNALS OF ONCOLOGY
Volume 24, Issue 8, Pages 2158-2165
Publisher
Oxford University Press (OUP)
Online
2013-04-11
DOI
10.1093/annonc/mdt115
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Identification of Unique MEK-Dependent Genes in GNAQ Mutant Uveal Melanoma Involved in Cell Growth, Tumor Cell Invasion, and MEK Resistance
- (2012) G. Ambrosini et al. CLINICAL CANCER RESEARCH
- Survival of 1,181 Patients in a Phase I Clinic: The MD Anderson Clinical Center for Targeted Therapy Experience
- (2012) J. Wheler et al. CLINICAL CANCER RESEARCH
- PI3K/AKT/mTOR Inhibitors in Patients With Breast and Gynecologic Malignancies HarboringPIK3CAMutations
- (2012) Filip Janku et al. JOURNAL OF CLINICAL ONCOLOGY
- Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trial
- (2012) Gerald S Falchook et al. LANCET
- Safety, pharmacokinetic, pharmacodynamic, and efficacy data for the oral MEK inhibitor trametinib: a phase 1 dose-escalation trial
- (2012) Jeffrey R Infante et al. LANCET ONCOLOGY
- Antitumor effects of the investigational selective MEK inhibitor TAK733 against cutaneous and uveal melanoma cell lines
- (2012) Erika von Euw et al. Molecular Cancer
- Survival in BRAF V600–Mutant Advanced Melanoma Treated with Vemurafenib
- (2012) Jeffrey A. Sosman et al. NEW ENGLAND JOURNAL OF MEDICINE
- Validation of the royal marsden hospital prognostic score in patients treated in the phase I clinical trials program at the MD Anderson Cancer Center
- (2011) Ignacio Garrido-Laguna et al. CANCER
- KIT mutations in ocular melanoma: frequency and anatomic distribution
- (2011) Michelle L Wallander et al. MODERN PATHOLOGY
- Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
- (2011) Paul B. Chapman et al. NEW ENGLAND JOURNAL OF MEDICINE
- BRAF Mutations in Advanced Cancers: Clinical Characteristics and Outcomes
- (2011) Hazem El-Osta et al. PLoS One
- New Response Evaluation Criteria in Solid Tumors (RECIST) Guidelines for Advanced Non–Small Cell Lung Cancer: Comparison With Original RECIST and Impact on Assessment of Tumor Response to Targeted Therapy
- (2010) Mizuki Nishino et al. AMERICAN JOURNAL OF ROENTGENOLOGY
- Revised RECIST Guideline Version 1.1: What Oncologists Want to Know and What Radiologists Need to Know
- (2010) Mizuki Nishino et al. AMERICAN JOURNAL OF ROENTGENOLOGY
- Phase I Oncology Studies: Evidence That in the Era of Targeted Therapies Patients on Lower Doses Do Not Fare Worse
- (2010) R. K. Jain et al. CLINICAL CANCER RESEARCH
- Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma
- (2010) Gideon Bollag et al. NATURE
- Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
- (2010) F. Stephen Hodi et al. NEW ENGLAND JOURNAL OF MEDICINE
- Integrating BRAF/MEK inhibitors into combination therapy for melanoma
- (2009) K S M Smalley et al. BRITISH JOURNAL OF CANCER
- A Randomized, Double-Blind, Placebo-Controlled, Phase II Study Comparing the Tolerability and Efficacy of Ipilimumab Administered with or without Prophylactic Budesonide in Patients with Unresectable Stage III or IV Melanoma
- (2009) J. Weber et al. CLINICAL CANCER RESEARCH
- Mutation analysis of the EGFR–NRAS–BRAF pathway in melanomas from black Africans and other subgroups of cutaneous melanoma
- (2009) Lars A. Akslen et al. MELANOMA RESEARCH
- Application of COLD-PCR for improved detection of KRAS mutations in clinical samples
- (2009) Zhuang Zuo et al. MODERN PATHOLOGY
- CTLA4 blockade with ipilimumab to treat relapse of malignancy after allogeneic hematopoietic cell transplantation
- (2008) A. Bashey et al. BLOOD
- Clinical outcome and prognostic factors for patients treated within the context of a phase I study: the Royal Marsden Hospital experience
- (2008) H-T Arkenau et al. BRITISH JOURNAL OF CANCER
- Phase I/II Study of Ipilimumab for Patients With Metastatic Melanoma
- (2008) Jeffrey S. Weber et al. JOURNAL OF CLINICAL ONCOLOGY
- Frequent somatic mutations of GNAQ in uveal melanoma and blue naevi
- (2008) Catherine D. Van Raamsdonk et al. NATURE
- Anti-CTLA4 Monoclonal Antibody Ipilimumab in the Treatment of Metastatic Melanoma: Recent Findings
- (2008) Marko Lens et al. Recent Patents on Anti-Cancer Drug Discovery
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now